Exhibit 10.9


 


EXECUTIVE EMPLOYMENT AGREEMENT


 


This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”)
is made and entered into as of February 18, 2019, by and between MDxHealth, Inc., a company incorporated in the state of Delaware and
with an office located at 15279 Alton Pkwy, Suite 100, Irvine, CA 92618 (“Company”), and Mr. Michael K. McGarrity
(“Executive”).


 


RECITALS


 


A. 
WHEREAS, the Company engages in the business of oncologic molecular diagnostics;


 


B. 
WHEREAS, the Company desires to employ Executive as the Chief Executive Officer of the Company and to direct Executive to serve as the
Chief Executive Officer of the MDxHealth group;


 


C. 
WHEREAS, the Executive desires to provide employment services to the Company on the terms and conditions set forth in this Agreement;


 


NOW, THEREFORE, in consideration of the mutual
covenants and conditions set forth below, the parties hereby agree as follows:


 


Article
I EMPLOYMENT AND DUTIES


 


1.1 
Position & Duties. Executive shall be employed as the Chief Executive Officer of the Company and, at the direction of the
Company, shall also serve as the Chief Executive Officer of the MDxHealth group. As such, Executive shall be an exempt salaried employee.
Executive shall report to the Board of Directors of MDxHealth SA (“Board”), an affiliate of the Company (“Parent”).
As the Chief Executive Officer, Executive shall have responsibility for the general business operations of the Company and the MDxHealth
group, subject to the guidelines, plans or policies as may be established, modified, or approved by the Board from time to time.


 


1.2 
Start Date. Executive will commence employment with the Company on February 18, 2019 (“Start Date”) or such other
date as mutually agree to by the parties.


 


1.3 
Location of Services. Unless the Company determines otherwise in its sole discretion, the principal place of business for the
performance of Executive’s duties hereunder shall be at the Company’s offices located in Irvine, California, subject to such
domestic and international travel as may be required to perform Executive’s duties hereunder. Executive acknowledges that frequent
and extensive international travel will be necessary for the performance of his duties and taking into account the location of Parent’s
headquarters in Belgium. Executive shall relocate to Irvine, California, as soon as reasonably possible following the execution of this
Agreement.


 


1.4 
At-Will Employment. Subject to Articles III and IV, Executive’s employment with the Company is “at-will,” and
either the Company or Executive may terminate this Agreement at any time and for any reason with or without cause. Subject to Articles
III and IV, the Company may also change Executive’s compensation, duties, assignments, responsibilities, and primary work location,
or the other terms and conditions of Executive’s employment at any time without advance notice. Executive acknowledges and agrees
that the Company is his sole employer within the MDxHealth group.


 






    1


     


    

 


1.5 
Other Business Affiliations. Subject to the provisions of Section 5.1, Executive agrees that, without the approval of the Board,
Executive shall not, during the period of employment with the Company, devote any time to any business affiliation which would interfere
with or derogate from Executive’s duties and obligations under this Agreement.


 


1.6 
Compliance with Laws. Executive agrees to comply with all applicable governmental laws, rules and regulations, and policies, standards
and regulations of the Company now existing or hereafter promulgated. Among other things, Executive agrees to pay special attention to
the medical fraud and abuse and anti-kickback laws, not just as they apply to the Company and its affiliates, but also as they apply
to Company’s and its affiliates’ relationships with other parties and with healthcare professionals. The Company and its
affiliates are committed to ensuring that their practices and procedures are compliant and that their relationships with other parties
and healthcare professionals benefit patients and enhances the practice of medicine.


 


Article
II COMPENSATION AND BENEFITS


 


2.1 
Base Salary. Executive shall be paid a gross annual base salary of $400,000 (“Base Salary”), less deductions
and withholding required by law or approved by Executive, paid in accordance with the Company’s normal and customary payroll practices.
The Board (or the Nominations and Remuneration Committee of the Board) will review the Base Salary annually; provided, however that any
increases in Base Salary are not guaranteed and will be determined by the Company in its sole discretion.


 


2.2 
Annual Bonus. In addition to the Base Salary described in Section 2.1, subject to the approval by the general shareholders meeting
of the Parent, for each full calendar year of employment with the Company (“Annual Bonus Period”), Executive shall
be eligible to earn an annual bonus of up to 50% of Executive’s then in effect Base Salary (“Potential Annual Bonus”).
For the calendar year 2019, the Potential Annual Bonus will be pro-rated for the partial year of employment. The amount and calculation
of the actual annual bonus will be based on the Executive’s and the Company’s achievement of performance goals established
in advance by the Board in its sole discretion and will require approval by the general shareholders meeting of the Parent, in accordance
with the applicable mandatory Belgian corporate governance rules (“Annual Bonus”). For avoidance of doubt, Executive
understands that, absent shareholder approval, applicable mandatory Belgian corporate governance rules generally mandate that certain
executive bonuses be partially structured over a two-year and three-year performance period rather than a single year period. The Annual
Bonus, if any, will be earned and paid no later than March 15th of the year following the Annual Bonus Period (“Payment Date”).
In the event Executive’s employment terminates for any reason other than for Cause prior to the end of the Annual Bonus Period,
Executive shall be eligible to receive a pro-rata Annual Bonus based on Executive’s period of employment during the applicable
calendar year and achievement by Executive and the Company of the objectives during that time period. In this case, the prorated Annual
Bonus, if any, will only be deemed earned and paid on the Payment Date. All bonus payments shall be made less deductions and withholdings
required by law or approved by Executive. Notwithstanding the above, for calendar year 2019, subject to compliance with any applicable
mandatory Belgian corporate governance rules, the following performance criteria, targets and weighting shall apply:


 


		●	Assuring sufficient
                                            funding for Parent (as to be further specified by the Board): 30%;



 


		●	Results top line /
                                            bottom line (as to be further specified by the Board): 30%;



 


		●	Strategic / corporate
                                            initiatives (as to be further specified by the Board): 40%.



 






    2


     


    

 


2.3 
Sign On Bonus. The Company will pay Executive a one time sign on bonus in the gross amount of $85,000.00, less deductions and
withholdings required by law or approved by Executive (“Sign On Bonus”). The Sign On Bonus will paid in the second
payroll following Executive’s Start Date. The Sign On Bonus is provided to facilitate the Executive’s relocation to Irvine,
California, and the Company will not provide supplemental reimbursement for relocation costs.


 


2.4 
Reimbursable Expenses. Upon submission of expense reports sufficient to substantiate the Company’s federal income tax deductions
for such expenses under the Internal Revenue Code of 1986, as amended (the “Code”), and in compliance with the expense
report procedures as may be established by the Company from time to time, the Company shall reimburse Executive for all reasonable business
expenses incurred in the performance of Executive’s duties hereunder on behalf of the Company.


 


2.5 
Benefits. Executive and his dependents will be eligible to participate in all group health, medical, dental, disability and insurance
plans, incentive, savings and retirement plans, and such other employee benefits (collectively, “Plans”), if any,
as the Company may establish for its executives and on the same terms and conditions as are generally applicable to executives of the
Company. Such Plans may be modified or terminated by the Company from time to time in accordance with the terms of the Plans. Executive’s
and his dependents’ participation in such plans may be limited to the extent the Company reasonably determines it is necessary
to avoid adverse tax consequences.


 


2.6 
Vacations, Holidays & Sick Leave. Executive shall be eligible to accrue up to thirteen and one third (13 1/3) hours of vacation
per month, which is equivalent to one hundred sixty (160) hours or twenty (20) days per full calendar year. The Company’s policies
and/or practices as are generally applicable to executive employees of the Company shall apply to Executive’s accrual and use of
vacation. Executive will be eligible to earn paid sick leave in accordance with the Company’s standard policy for similarly situated
employees and applicable law. Executive will also be entitled to all paid holidays provided to the Company’s executive employees
in California.


 






    3


     


    

 


2.7 
Stock Options.


 


(a) 
Grant Terms. Subject to approval by the Board at its next regularly scheduled Board meeting following the date of this Agreement,
Executive shall be granted an option to purchase 1,500,000 common shares of the Parent, which represents approximately 2.5% of the current
share capital of the Parent (the “Stock Option”). The per share exercise price of the Stock Option shall be equal
to the higher of (i) average price of the common shares of the Parent on Euronext during the period of 30 days preceding the date of
the grant, or (ii) the closing price on the Euronext of the underlying shares on the date of grant. The Stock Option shall vest in three
equal annual installments on each anniversary of the Start Date. The Stock Option shall be subject to such other terms and conditions
set forth in the stock option plan(s) (“Plan”) pursuant to which it is granted and the agreement evidencing the grant.


 


(b) 
Accelerated Vesting. In the event of a Change of Control (as defined below) and provided the Board approves this provision in
connection with the approval of the Stock Option, the Stock Option shall vest in full upon a Change of Control, except that in the case
of a Change of Control that occurs during the first six (6) months following the Start Date, the Stock Option shall only vest with respect
to 50% of the underlying shares subject to the Stock Option.


 


(c) 
Change of Control. For purposes of this Agreement, “Change of Control” means (i) the occurrence of any of the
following events: the consolidation, merger, reorganization, sale of all or substantially all of the assets or capital stock (including
a control group tender offer) of the Company or Parent, (ii) completion of any other business combination in which Parent is not the
surviving entity, or (iii) the announcement of the launch of public tender offer for all of the Parent’s voting securities that
are not yet owned by the person making the tender offer (“Public Tender Offer”) that is unconditional, or the announcement
that a conditional Public Tender Offer that has previously been launched has become unconditional.


 


Article
III TERMINATION


 


3.1 
Termination Due to Executive’s Death. The Executive’s employment under this Agreement shall automatically terminate
upon the death of the Executive.


 


3.2 
Termination Due to Executive’s Disability. To the extent permissible under applicable law, the Company shall have the right,
exercisable at any time, to terminate the Executive’s employment under this Agreement with immediate effect upon the Executive’s
Disability (as defined below) by providing written notice in accordance with Section 6.4. For purposes of this Agreement, “Disability”
shall mean the Executive’s inability to perform the essential duties of Executive’s position for either one hundred twenty
(120) consecutive calendar days or one hundred fifty (150) calendar days in any twelve (12) month period by reason of any medically determined
physical or mental impairment with or without a reasonable accommodation, consistent with the requirements of applicable state and federal
law. In the event of any dispute regarding the existence of a Disability, the matter will be resolved by the determination of a physician
qualified to practice medicine in the State of California (a “Physician”), whose identity is mutually agreed to by
both parties, and whose determination shall be final and binding. If the parties cannot agree on a Physician, each party shall select
one Physician, and those two Physicians shall select a third Physician to make the Disability determination, which shall be final and
binding.


 






    4


     


    

 


3.3 
Termination by the Company for Cause. The Company shall have the right, exercisable at any time, to terminate the Executive’s
employment under this Agreement with immediate effect for Cause (as defined below) by providing written notice in accordance with Section
6.4. For purposes of this Agreement, “Cause” shall mean: (i) Executive’s gross negligence or willful misconduct
in the performance of Executive’s duties or willful or repeated failure or refusal to perform any duties reasonably requested by
the Board, provided such duties are consistent with his title and position; (ii) Executive’s act or omission which constitutes
misrepresentation or fraud and which causes, or is reasonably likely to cause, more than de minimis harm to the Company, Parent or its
affiliates (together with Parent, the “Group”), including its or their business or reputation; (iii) Executive’s
material violation of the Company’s or the Group’s lawful and material policies or procedures of which the Executive has
had prior written notice or any laws, regulations or rules that are material to the business of the Company or the Group; (iv) Executive’s
material breach of this Agreement or the Proprietary Information and Inventions Agreement; (v) Executive’s commission, indictment
on charges related to, conviction of, or plea of guilty or no contest to a felony or similar or equivalent charge pursuant to applicable
law, involving dishonesty that caused, or is reasonable likely to cause, more than de minimis harm to the Company or any entity in the
Group, including its or their business or reputation; (vi) Executive’s misappropriation of Company or Group assets or breach of
his fiduciary duties to the Company or the Group; provided, however, that a termination shall not be a termination for Cause with respect
to any event or circumstance described in clauses (i), (iii), or (iv) that is reasonably susceptible of cure (as determined by the Company
in its reasonable discretion) (a “Curable Event”) unless (a) Executive has been given written notice of the Curable
Event and at least ten (10) business days to cure, and (b) the Curable Event or circumstance remains uncured at the end of such ten (10)
business day period; provided, however, that if such failure to cure cannot reasonably be remedied within such ten (10) business day
period (as determined by the Company in its reasonable discretion), it shall not constitute Cause hereunder if the Executive shall commence
such remedy within such ten (10) business day period and thereafter diligently pursues such remedy and causes its completion within thirty
(30) days thereafter.


 


3.4 
Resignation by Executive For Good Reason. The Executive may terminate his employment for Good Reason (as defined below) in accordance
with the terms of this Section 3.4. For purposes of this Agreement, “Good Reason” shall mean: (i) a material diminution
in the character or scope of Executive’s duties, responsibilities, or authority, (ii) a material reduction in Base Salary other
than a reduction that is proportionate to any general reduction in base salaries of executive officers of the Company and/or Parent;
or (iii) the Company’s material breach of this Agreement, including, for the avoidance of any doubt, a breach of Section 6.20 hereof;
provided, however, that for an event to constitute an event of Good Reason under this Section 3.4, the Executive must (a) provide the
Company with written notice in accordance with Section 6.4 of Executive’s intent to terminate employment and a detailed description
of the event Executive believes constitutes Good Reason within thirty (30) days after the initial existence of the event, and (b) the
Company shall have sixty (60) days after Executive provides the notice described above to cure the event that constitutes Good Reason
(the “Cure Period”). Provided that the Company has not cured the event reportedly giving rise to Good Reason, Executive
will have ninety (90) days following the end of the Cure Period to terminate Executive’s employment for Good Reason, after which
Good Reason will no longer exist with respect to the event to which such cure period applied.


 






    5


     


    

 


3.5 
Termination by the Company without Cause or Resignation by Executive Without Good Reason. The Company may terminate Executive’s
employment at any time without Cause, and the Executive may terminate the Executive’s employment without Good Reason, in each case
upon thirty (30) days prior written notice to the other party in accordance with Section 6.4.


 


Article
IV COMPENSATION UPON TERMINATION


 


4.1 
Final Pay Upon Termination. Upon the termination of Executive’s employment with the Company for any reason, the Company
shall pay to Executive (or his beneficiaries) in accordance with California law the unpaid portion of the Base Salary earned through
the date of termination, any Annual Bonus earned prior to termination but remaining unpaid, and all accrued but unused paid vacation
leave (“Final Pay”), less deductions and withholdings required by law. Final Pay will be paid in accordance with California
law.


 


4.2 
Termination by the Company for Cause, due to Executive’s Death or Disability, or Executive’s Resignation without Good
Reason. If the Company terminates Executive for Cause, or due to Executive’s Death or Disability, or Executive resigns without
Good Reason, Executive shall be entitled to receive the Final Pay only, and no severance, compensation or benefits shall be owed or paid
by the Company.


 


4.3 
Termination by the Company without Cause or Executive’s Resignation for Good Reason. Although Executive is employed at all
times on an “at-will” basis, if the Company terminates Executive without Cause or Executive resigns for Good Reason, Executive
shall be eligible to receive as severance upon the execution and non-revocation of a Release (as defined below) an amount equal to six
(6) month’s of Executive’s Base Salary in effect at the time of the termination, less deductions and withholdings required
by law (“Severance Pay”). As of the first anniversary of the Start Date, the Severance Pay will increase to twelve
(12) months of Base Salary, less deductions and withholdings required by law. For the avoidance of doubt, this provision will continue
to apply following a Change of Control provided that the conditions herein are satisfied.


 


4.4 
Timing of Severance Payment and Release Requirement. The Severance Pay shall be paid to Executive in a lump sum within ten (10)
business days following the effective date of a general release of all claims by Executive in a form provided by and acceptable to the
Company (“Release”), which Release must be effective and irrevocable no later than fifty-five (55) days after the
termination of Executive’s employment.


 


Article
V NONCOMPETITION DURING EMPLOYMENT


 


5.1 
Noncompetition During Employment. During his employment, Executive shall devote his full time and efforts to the business of the
Company and will not directly or indirectly, engage, individually or as an officer, director, employee, consultant, advisor, partner
or co-venturer, or as a stockholder or other proprietor owning more than a five percent (5%) interest in any firm, corporation, partnership
or other organization (in case of any such ownership or participation) in any enterprise or business that competes directly or indirectly
with the products and/or services of the Company or the Group. Executive shall furnish to the Board a detailed statement of any outside
employment or consulting services in which Executive seeks to engage or invest, and, as from time to time requested by the Board, resubmit
for approval a detailed statement thereof. In the event the Board determines in good faith that such violation or conflict exists, Executive
shall refrain from such employment, consulting services or investment. It is intended and agreed that during the term of Executive’s
employment, Executive will knowingly perform no act which may confer any competitive benefit or advantage upon any enterprise or business
competing with Company or the Group.


 






    6


     


    

 


5.2 
Non-Solicitation. Executive agrees that during his employment and for a period of one (1) year after the termination of his employment
for any reason, and within the geographical regions in which the Company or the Group does business, Executive shall not induce or attempt
to induce, either directly or indirectly, any employee, agent or consultant of the Company or the Group to terminate his or her association
with the Company or the Group or attempt by any means to persuade or incite such individuals to accept another employment or engagement
or to leave the Company or the Group. The Company and Executive agree that the provisions of this Section 5.2 are necessary to protect
the legitimate business interests of the Company.


 


5.3 
In the event of the breach or threatened breach by Executive of any of the provisions of this Article 5, the Company, in addition to
all other remedies available to it at law or in equity, shall be entitled to seek preliminary or permanent injunctive relief and/or specific
performance to enforce the provisions set forth in this Article 5.


 


Article
VI MISCELLANEOUS PROVISIONS


 


6.1 
Proprietary Information and Inventions Agreement. In conjunction with the execution of this Agreement, Executive will execute
and enter into the Company’s standard Proprietary Information and Inventions Agreement, attached hereto as Exhibit 1, the
terms of which shall be incorporated into this Agreement.


 


6.2 
No Breach of Duty. Executive represents that Executive’s performance of this Agreement and employment with the Company does
not and will not breach any agreement or duty to keep in confidence proprietary information acquired by Executive before his employment
with the Company. Executive has not and will not enter into any agreement, either written or oral, in conflict with this Agreement. Executive
represents that he is not currently restricted from being employed by the Company or entering into this Agreement.


 






    7


     


    

 


6.3 
Arbitration. Except for workers’ compensation claims, disputes solely before government agencies (including but not limited
to the NLRB or EEOC), unemployment insurance claims, and other claims which may not be arbitrated as a matter of law, Executive and the
Company agree that any and all disputes, controversies, or claims, whether based in contract, tort, common or statutory law, between
Executive and the Company and/or its agents, and whether arising under or relating to this Agreement, Executive’s employment with
the Company, the termination of Executive’s employment, or any other manner of the parties’ relationship (“Arbitrable
Claims”) shall be resolved by final and binding arbitration conducted pursuant to the Federal Arbitration Act. Executive and
the Company agree that arbitration shall be exclusive, final and binding remedy for all Arbitrable Claims, and Executive, the Company
and its agents hereby waive any rights each may have to a jury trial in regard to Arbitrable Claims. Executive and the Company further
agree that the arbitrator shall have the sole authority to determine the arbitrability of Arbitrable Claims. The arbitration shall be
conducted by a single arbitrator before JAMS in Irvine, California (or other mutually agreed upon city) under the JAMS Employment Arbitration
Rules and Mediation Procedures and the JAMS Policy on Employment Arbitration Minimum Standards of Procedural Fairness, if applicable,
in effect on the date this Agreement is signed (“JAMS Rules”), except as expressly set forth herein or where such
rules are not in compliance with applicable state or federal law. A copy of the JAMS Rules is available for review through the Company
by submitting a request to the Human Resources Department, by contacting JAMS at telephone number 800¬352-5267, or at JAMS’
website at www.jamsadr.com. Both Executive and the Company shall be entitled to file dispositive motions before the arbitrator to the
same extent as would be allowed had the dispute been heard in a court of law having jurisdiction over the parties’ claims or counterclaims.
The arbitrator shall have the same authority as a court to award equitable relief, damages, costs, and fees as provided by law or the
applicable JAMS Rules for the particular claims asserted. Executive and the Company shall follow the JAMS Rules applicable to initial
filing fees, but in no event will Executive be responsible for any portion of those fees in excess of the filing or initial appearance
fees applicable to court actions in the jurisdiction where the arbitration will be conducted. The Company otherwise shall pay all costs
and expenses unique to arbitration, including without limitation the arbitrator’s fees. The arbitrator must follow applicable law
and may award only those remedies that would have applied had the matter been heard in court. All Arbitrable Claims must be brought within
the statutes of limitations applicable to such claims. The arbitrator’s decision must be in writing and contain findings of fact
and conclusions of law. Judgment may be entered on the arbitrator’s decision in any court having jurisdiction. This Agreement affects
Executive’s ability to participate in class, collective or representative actions. Both the Company and Executive agree to bring
any dispute in arbitration on an individual basis only, and not on a class, collective, or private attorney general representative basis
on behalf of others. There will be no right or authority for any dispute to be brought, heard or arbitrated as a class, collective, representative
or private attorney general action, or as a member in any such class, collective, representative or private attorney general proceeding
(“Class Action Waiver”). This Class Action Waiver does not apply to any claim Executive brings in arbitration as a private
attorney general solely on his own behalf and not on behalf of others. Notwithstanding any other provision of this Agreement or the JAMS
Rules, disputes regarding the validity, enforceability or breach of the Class Action Waiver may be resolved only by a civil court of
competent jurisdiction and not by an arbitrator.


 


6.4 
Notices. All Notices and all other communications which are required to be given under this Agreement must be in writing and shall
be deemed to have been duly given when (i) personally delivered, (ii) mailed by United States registered or certified mail postage prepaid,
(iii) sent via a nationally recognized overnight courier service, (iv) sent via e-mail to the recipient, in each case as follows:


 


	If to Company:	MDxHealth, Inc.
	 	15279 Alton Parkway, Suite 100
	 	Irvine CA 92618,
	 	Attn: General Counsel (Confidential)
	 	Email: joseph.sollee@mdxhealth.com



 






    8


     


    

 


	If to Executive:	Michael McGarrity



 


or such other address or addresses as either party hereto shall have
designated by notice in writing to the other party hereto. Such notices shall be deemed given on the date on which personally served
or emailed, or if by mail or courier on the third (3rd) day after being posted or on the date of actual receipt, whichever is earlier.


 


6.5 
Independent Counsel. Each party acknowledges that it has been represented by independent counsel of its choice, or has had the
opportunity to be represented by independent counsel of its choice, and that to the extent, if any, that it desired, has availed itself
of this right and opportunity throughout all negotiations that have preceded the execution of this Agreement, and that it has executed
the same with the consent and upon the advice of such independent counsel. Accordingly, any rule of law or any legal decision that would
require interpretation of any claimed ambiguities in this Agreement against the drafting party has no application and is expressly waived,
and the parties agree to all of the provisions in this Agreement based on the advice of their respective counsel.


 


6.6 
Conditions to Employment. This Agreement and Executive’s employment are also contingent upon Executive’s proof of
identity and work eligibility. Under the Immigration Reform and Control Act of 1986, employers are required to verify the identity and
employment eligibility of all new hires within three (3) business days of their first day of work. To assist the Company in complying
with this requirement, Executive is required to bring appropriate documents with him on his first day. This Agreement and Executive’s
employment are contingent upon successful completion of a reference check and/or background check.


 


6.7 
Taxes. All payments under this Agreement will be made less deductions and withholdings required by law.


 


6.8 
The Company’s Property. The Executive, upon the termination of Executive’s employment for any reason or, if earlier,
upon the Company’s reasonable request, shall promptly return all Property (as defined below) that had been entrusted or made available
to Executive by the Company. For purposes of this Agreement, “Property” means all records, files, memoranda, reports,
price lists, customer lists, drawings, plans, sketches, keys, codes, computer hardware and software and other property of any kind or
description prepared, developed or acquired by Executive during Executive’s employment by the Company or its predecessors in interest
(and any duplicates of any such property) together with any and all information, ideas, concepts, discoveries, and inventions and the
like conceived, made, developed or acquired at any time by Executive individually or with others during Executive’s employment
that relate to the Company’s business.


 


6.9 
Resignation From Board. The Executive, upon the termination of Executive’s employment shall promptly resign from the Board,
Board of Directors of the Company and each of its affiliates, subsidiaries, parent company, successors and assigns.


 






    9


     


    

 


6.10 
Section 409A of the Code. It is the intention of the parties to this Agreement that no payment or entitlement pursuant to this
Agreement will give rise to any adverse tax consequences under Section 409A of the Code (“Section 409A”) and that such payments
or entitlements to which the Executive is or could become entitled to under this Agreement are intended to be exempt from or comply with
Section 409A, with the payments intended to be exempt under the “short-term deferral” and “separation pay” exceptions
to the maximum extent permitted under Section 409A, and this Agreement shall be interpreted and administered in a manner consistent with
such intent. Further, no effect shall be given to any provision herein in a manner that reasonably could be expected to give rise to
adverse tax consequences under Section 409A. Notwithstanding the foregoing, the Company may unilaterally amend the terms of this Agreement
to avoid the application of, or to comply with, Section 409A, in a particular circumstance or as necessary or desirable to satisfy any
of the requirements under Section 409A or to mitigate any additional tax, interest and/or penalties that may apply under Section 409A
if exemption or compliance is not practicable, but the Company shall not be under any obligation to make any such amendment. For purposes
of Section 409A, each installment payment provided under this Agreement shall be treated as a separate and distinct payment. Nothing
in this Agreement shall provide a basis for any person to take action against the Company or any affiliate thereof based on matters covered
by Section 409A, including the tax treatment of any amount paid under the Agreement, and neither the Company nor any of its affiliates
shall under any circumstances have any liability to the Executive or his estate or any other party for any taxes, penalties or interest
due on amounts paid or payable under this Agreement, including taxes, penalties or interest imposed under Section 409A.


 


Without limiting the generality of the foregoing and anything in this
Agreement to the contrary notwithstanding, if amounts or benefits payable by reference to the timing of the Executive’s termination
of employment constitute non-qualified deferred compensation subject to Section 409A, as determined in the Company’s sole discretion,
(i) such amounts or benefits shall not be paid unless the Executive experiences a “separation from service” (within the meaning
of Section 409A), (ii) to the extent that any payment period conditioned on the Executive’s execution of a release commences in
one calendar year and ends in the subsequent calendar year, such amounts or benefits shall be paid in the second calendar year; and (iii)
if Executive is a “specified employee” (within the meaning of Section 409A) as of the date of Executive’s separation
from service, such amounts or benefits shall not be paid until the date that is six months and one day following the date of Executive’s
separation from service, or if earlier, the date of Executive’s death.


 


6.11 
Golden Parachute. In the event that the benefits provided for in this Agreement (together with any other benefits or amounts)
otherwise constitute “parachute payments” within the meaning of Section 280G of the Code and would, but for this Section
6.11 be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then Executive’s
benefits under this Agreement shall be reduced to the extent necessary such that no portion of the such benefits would be subject to
the Excise Tax. In the event of a reduction of benefits hereunder, the Consulting Firm (as defined below) shall determine which benefits
shall be reduced so as to achieve the principle set forth in the preceding sentence. In no event shall the foregoing be interpreted or
administered so as to result in an acceleration of payment or further deferral of payment of any amounts (whether under this Agreement
or any other arrangement) in violation of Section 409A. Unless the Company and Executive otherwise agree in writing, all determinations
required to be made under this Section 6.11, including the manner and amount of any reduction in Executive’s benefits under
this Agreement, and the assumptions to be utilized in arriving at such determinations, shall be made in writing in good by the accounting
firm designated by the Company (the “Consulting Firm”). In the event that the Consulting Firm (or any affiliate thereof)
is unable or unwilling to act, Executive may appoint a nationally recognized public accounting firm to make the determinations required
hereunder (which accounting firm shall then be referred to as the Consulting Firm hereunder). All fees and expenses of the Consulting
Firm shall be borne solely by the Company, and the Company shall enter into any agreement requested by the Consulting Firm in connection
with the performance of the services hereunder. For purposes of making the calculations required by this Section 6.11, the Consulting
Firm may make reasonable assumptions and approximations concerning the application of Sections 280G and 4999 of the Code. The Company
and Executive shall furnish to the Consulting Firm such information and documents as the Consulting Firm may reasonably request to make
a determination under this Section 6.11.


 






    10


     


    

 


6.12 
Legal Representatives. Upon the death or disability of Executive, any payments due under this Agreement shall be paid to Executive’s
legal representatives.


 


6.13 
Representations. Executive represents that he has not been debarred nor received notice of any action or threat with respect to
his debarment under the provisions of the Generic Drug Enforcement Act of 1992, 21 U.S.C. § 335 (a). Executive agrees promptly to
notify Company upon receipt of any such notice and further agree, upon Company’s request, to provide a separate written certification,
on a form provided by Company, to this effect.


 


6.14 
Shareholder Approval by Parent. The provisions of this Agreement that contain obligations for the Company and/or create rights
for the Executive in function of a change of control over the Parent or the Group are subject to the approval by the general shareholders
meeting of the Parent in accordance with article 556 of the Belgian Company Code. Other provisions in relation to variable remuneration
are subject to the approval by the general shareholders meeting of the Parent.


 


6.15 
Severability. If any term, provision, covenant or condition of this Agreement is held to be invalid, void, or unenforceable, the
remainder of the provisions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated
thereby.


 


6.16 
Survival. Articles III, IV, V, and VI shall survive the termination of this Agreement.


 


6.17 
Entire Agreement; Employment Amendments; Waiver. This Agreement, together with the Proprietary Information and Inventions Agreement,
is the entire agreement between the parties hereto concerning the subject matter hereof and supersedes and replaces all prior or contemporaneous
agreements or understandings between the parties. This Agreement may not be amended or modified in any manner, except by an instrument
in writing signed by Executive and the President or Vice President of the Company. Failure of either party to enforce any of the provisions
of this Agreement or any rights with respect thereto or failure to exercise any election provided for herein shall in no way be considered
to be a waiver of such provisions, rights or elections or in any way effect the validity of this Agreement. The failure of either party
to exercise any of said provisions, rights or elections shall not preclude or prejudice such party from later enforcing or exercising
the same or other provisions, rights or elections which it may have under this Agreement.


 






    11


     


    

 


6.18 
Governing Law. This Agreement shall be governed by and construed in all respects in accordance with the laws of the State of California.
The Executive acknowledges and agrees that the Company is his sole employer, and that his employment relationship is only subject to
California law. With the exception of “Arbitrable Claims” as defined in Section 6.3, the federal courts and/or state courts
of the State of California, Orange County shall have exclusive jurisdiction to adjudicate any dispute arising out of this Agreement and/or
employment relationship or termination thereof and Executive consents to such jurisdiction and venue.


 


6.19 
Attorneys’ Fees. In the event of any action for the breach of this Agreement, the prevailing party shall be entitled to
reasonable attorneys’ fees, costs and expenses incurred in connection with such action.


 


6.20 
Successors And Assigns. This Agreement and Executive’s obligations hereunder will be binding upon his heirs, executors,
administrators and other legal representatives and will be for the benefit of the Company, its successors, and its assigns. The Company
shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all
of the business and/or assets of the Company or the Parent to expressly assume and agree to perform this Agreement in the same manner
and to the same extent that the Company would be required to perform it if no such succession had taken place.


 


IN WITNESS WHEREOF, the parties have executed this Agreement as of
the day and year first above written.


 


	“Executive”	 	“Company”
	 	 	 
	By:	/s/ Michael K. McGarrity	 	By:	/s/ Koen Hoffman
	 	Michael K. McGarrity	 	 	 
	 	 	 	 	/s/ Walter Narajowski
	 	 	 	 	 
	 	 	 
	 	 	 	/s/ Joseph Sollee
	 	 	 	Joseph Sollee
	 	 	 	EVP Corp Dev & General Counsel
	 	 	 	February 18, 2019



 






    12


     


    

 


Exhibit 1


 


PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT


 


This PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT (“Agreement”),
effective as of February, 18, 2019, is executed by me, Michael McGarrity, in favor of MDxHealth, Inc. (“Company”).


 


As a condition of my employment by Company, and
in consideration of my employment and the compensation previously and hereafter paid to me by Company, I agree to the following:


 


		1.	PROTECTION
                                            OF CONFIDENTIAL INFORMATION



 


(a) 
Company Information. I acknowledge that during my employment by the Company I will have access to confidential information of
the Company and its affiliates, subsidiaries, parent company, successors and assigns (collectively, “Affiliated Entities”;
references to Company in this Section 1 include Affiliated Entities). I agree at all times during my employment with the Company and
following termination thereof for any reason, to hold in the strictest confidence, and not use, except for the benefit of the Company,
or to disclose to any person, firm or corporation without written authorization of the Board of Directors of MDxHealth SA, any Company
Confidential Information. I understand that my unauthorized use or disclosure of Company Confidential Information during my employment
will lead to disciplinary action, up to and including immediate termination and legal action by the Company. I understand that “Company
Confidential Information” means any non-public information that relates to the actual or anticipated business, research or
development activities of the Company, or to the Company’s technical data, trade secrets or know-how, including, but not limited
to, research, product plans or other information regarding the Company’s products or services and markets therefor, software, source
code, developments, inventions, discoveries, processes, formulas, technology, documentation, designs, drawings, engineering processes,
data, marketing information, customer lists and customers, suppliers, employees, financial and other business information; provided,
however Company Confidential Information does not include any of the foregoing items to the extent the same have become publicly known
and made generally available through no wrongful act of mine or of others. I understand that nothing herein is intended to preclude or
dissuade me from engaging in activities protected by state and federal law, including the National Labor Relations Act such as discussing
wages, benefits, or terms and conditions of employment, including discussions regarding forming, joining or supporting labor unions,
raising complaints about working conditions for my and my fellow employees’ mutual aid or protection or other legally protected
activities under applicable law.


 


(b) 
Former Employer Information. I agree that during my employment with the Company, I will not improperly use, disclose, or induce
the Company to use any proprietary information or trade secrets of any former or concurrent employer, or any other company, person, or
entity. I further agree that I will not bring onto the premises of the Company or transfer onto the Company’s technology systems
any unpublished document, proprietary information or trade secrets belonging to any such employer, company, person or entity unless consented
to in writing by both the Company and such employer, company, person or entity.


 






    13


     


    

 


(c) 
Third Party Information. I recognize that the Company may have received and in the future may receive from third parties associated
with the Company, e.g., the Company’s customers, suppliers, licensors, licensees, partners, joint venturers or collaborators (“Associated
Third Parties”) their confidential or proprietary information (“Associated Third Party Confidential Information”).
By way of example, Associated Third Party Confidential information may include the practices, technology and requirements of Associated
Third Parties, and information related to the business conducted between the Company and such Associated Third Parties. I agree at all
times during my employment with the Company and thereafter to hold in the strictest confidence, and not to use or to disclose to any
person, firm or corporation any Associated Third Party Confidential Information, except as necessary in carrying out my work for the
Company consistent with the Company’s agreement with such Associated Third Parties. I understand that my unauthorized use or disclosure
of Associated Third Party Confidential Information during my employment will lead to disciplinary action, up to and including immediate
termination and legal action by the Company.


 


(d) 
Immunity From Liability For Confidential Disclosure Of Trade Secret(s). Pursuant to the Defend Trade Secrets Act of 2016 (18 U.S.C.
1833(b)), I shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade
secret that is made in confidence either directly or indirectly to a Federal, State, or local government official, or to an attorney,
solely for the purpose of reporting or investigating, a violation of law. I shall not be held criminally or civilly liable under any
Federal or State trade secret law for the disclosure of a trade secret made in a complaint, or other document filed in a lawsuit or other
proceeding, if such filing is made under seal. If I file a lawsuit alleging retaliation by the company for reporting a suspected violation
of the law, I may disclose the trade secret to my attorney and use the trade secret in the court proceeding, so long as any document
containing the trade secret is filed under seal and does not disclose the trade secret, except pursuant to court order. This paragraph
will govern to the extent it may conflict with any other provision of this Agreement.


 


(e) 
Protected Rights. No sections in this Agreement, including the sections addressing my confidentiality obligations, is intended
to or shall limit, prevent, impede or interfere in any way with my right, without prior notice to the Company, to provide information
to the government, participate in investigations, testify in proceedings regarding the Company’s past or future conduct, or engage
in any activities protected under whistleblower statutes.


 


		2.	INVENTIONS
                                            AND ORIGINAL WORKS



 


(a) 
Inventions And Original Works Retained And Licensed To The Company. I have attached hereto as Exhibit A, a list describing
all inventions, discoveries, original works of authorship, developments, improvements, and trade secrets, which were conceived in whole
or in part by me prior to my employment with the Company to which I have any right, title or interest, which are subject to California
Labor Code Section 2870 attached hereto as Exhibit B, and which relate to the Company’s proposed business, products, or
research and development (“Excluded Inventions”); or, if no such list is attached, I represent and warrant that there
are no such Excluded Inventions. Furthermore, I represent and warrant that the inclusion of any Excluded Inventions on Exhibit A
of this Agreement will not materially affect my ability to perform all obligations under this Agreement. If, in the course of my employment
with the Company, I incorporate into or use in connection with any product, process, service, technology or other work by or on behalf
of Company any Excluded Invention, I hereby grant to the Company a nonexclusive, royalty-free, fully paid-up, irrevocable, perpetual,
worldwide license, with the right to grant and authorize sublicenses, to make, have made, modify, use, import, offer for sale, and sell
such Excluded Invention as part of or in connection with such product, process, service, technology or other work and to practice any
method related thereto.


 






    14


     


    

 


(b) 
Inventions And Original Works Assigned To The Company. I agree that I will promptly make full written disclosure to the Company,
will hold in trust for the sole right and benefit of the Company, and I hereby assign and transfer to the Company, or its designee, all
my worldwide right, title, and interest in and to (i) any and all inventions, original works of authorship, developments, concepts, improvements,
designs, discoveries, know-how, ideas, software, compositions of matter and trade secrets, whether or not patentable or registrable under
patent, copyright or similar laws, which I may solely or jointly conceive, create, develop, reduce to practice, or otherwise make (or
cause to be conceived, created, developed, reduced to practice or made), during the entire period of time I am in the employ of the Company
(including during my off-duty hours), or with the use of Company’s equipment, supplies, facilities, or Company Confidential Information,
except as provided in Section 2(g) below (collectively referred to as “Inventions”) (ii) any and all trade secrets,
patent rights, copyrights, moral rights, and other intellectual property rights anywhere in the world (collectively referred to as “Intellectual
Property Rights”) embodied in or related to such Inventions. I further acknowledge that all original works of authorship which
are made by me (solely or jointly with others) within the scope of and during the period of my employment with the Company and which
are protectable by copyright are “works made for hire,” as that term is defined in the United States Copyright Act, and the
Company will be considered the author and owner of such works. I understand and agree that the decision whether or not to commercialize
or market any Inventions is within the Company’s sole discretion and for the Company’s sole benefit and that no royalty or
other consideration will be due to me as a result of the Company’s efforts to commercialize or market any such Inventions.


 


(c) 
Moral Rights. To the extent permitted by applicable law, I assign to the Company all “moral rights” I may have in
any Inventions, except as provided in Section 2(g) below. If and to the extent an assignment or transfer of any Moral Rights is not valid
or enforceable under any applicable law, I grant the Company a worldwide, unlimited, royalty-free right and license in and to, and I
hereby forever waive and agree never to assert, any and all Moral Rights I may have in or with respect to any Inventions even after termination
of my employment or work on behalf of the Company. “Moral Rights” mean any rights to attribution or claim authorship
of a work of authorship, to object to or prevent the modification of any work of authorship, or to withdraw from circulation or control
the publication or distribution of any work, and any similar right, existing under judicial or statutory law of any country or jurisdiction
in the world, or under any treaty, regardless of whether or not such right is denominated or generally referred to as a “moral
right.”


 


(d) 
Assignment of Claims. I further perpetually, irrevocably, and unconditionally assign, transfer, and convey to Company and its
successors and assigns all claims for past, present and future infringement or misappropriation of the Inventions, including all rights
to sue for and to receive and recover all past, present and future profits and damages accruing from any infringement, misappropriation
or violation of Intellectual Property Rights in the Inventions.


 






    15


     


    

 


(e) 
Maintenance of Records. I agree to keep and maintain adequate, accurate and current written records of all Inventions made by
me (solely or jointly with others) during the term of my employment with the Company. These records will be in the form of notes, sketches,
drawings, electronic files, reports and any other format that may be specified by the Company. Such records will be available to and
remain the sole property of the Company at all times.


 


(f) 
Further Assurances. I agree to assist the Company, or its designee, at the Company’s expense, in every proper way to secure
the Company’s rights in the Inventions and any rights relating thereto in any and all countries, including the disclosure to the
Company of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments
and all other instruments which the Company shall deem proper or necessary in order to apply for, register, obtain, maintain, defend,
and enforce such rights and in order to assign and convey to the Company, its successors, assigns, and nominees the sole and exclusive
rights, title and interest in and to such Inventions and any rights relating thereto, and testifying in a suit or other proceeding relating
to such Inventions and any rights relating thereto. I further agree that my obligation to execute or cause to be executed, when it is
in my power to do so, any such instrument or papers shall continue after the termination of this Agreement. If the Company is unable
because of my mental or physical incapacity or for any other reason to secure my signature with respect to any Inventions including,
without limitation, to apply for or to pursue any application for any United States or foreign patents or copyright registrations covering
such Inventions, then I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent
and attorney in fact, to act for and in my behalf and stead to execute and file any papers, oaths and to do all other lawfully permitted
acts with respect to such Inventions with the same legal force and effect as if executed by me.


 


(g) 
Exception to Assignments. I understand that the provisions of this Agreement requiring assignment to the Company do not apply
to any invention which qualifies fully under the provisions of Section 2870 of the California Labor Code, a copy of which is attached
hereto as Exhibit B. I will advise the Company promptly in writing of any inventions, original works of authorship or trade secrets
that I believe meet the criteria in California Labor Code Section 2870; and I will at that time provide to the Company in writing all
evidence necessary to substantiate that belief.


 


		3.	NO
                                            BREACH OF DUTY



 


I represent that my performance of all the terms
of this Agreement and as an employee of the Company does not, and to the best of my present knowledge and belief, will not breach any
agreement or duty to keep in confidence proprietary information acquired by me in confidence or in trust prior to my employment by the
Company. I agree I will not enter into any agreement either written or oral in conflict with the terms of this Agreement. I am not at
the present time restricted from being employed by the Company or entering into this Agreement. I represent that I have no other agreements,
relationships or commitments to any other person or entity that conflict with my obligations to the Company under this Agreement or my
ability to become employed and perform the services for which I am being hired by the Company. I further agree that if I have signed
a confidentiality agreement or similar type of agreement with any former employer or other entity, I will comply with the terms of any
such agreement to the extent that its terms are lawful under applicable law. I represent and warrant that after undertaking a careful
search (including searches of my computers, cell phones, electronic devices and documents), I have returned all property and confidential
information belonging to all prior employers.


 






    16


     


    

 


		4.	TERMINATION
                                            CERTIFICATION



 


Upon separation from employment with the Company,
I agree to immediately sign and deliver to the Company the “Termination Certification” attached hereto as Exhibit C.
I also agree to keep the Company advised of my home and business address for a period of three (3) years after termination of my employment
with the Company, so that the Company can contact me regarding my continuing obligations provided by this Agreement.


 


		5.	NOTIFICATION
                                            OF NEW EMPLOYER



 


In the event that I leave the employ of the Company,
I hereby grant consent to notification by the Company to my new employer about my obligations under this Agreement.


 


		6.	USE
                                            AND RETURN OF COMPANY PROPERTY



 


I will not remove (either physically or electronically)
any property belonging to the Company or MDxHealth group, from the Company’s or MDxHealth group’s premises, except as required
in the ordinary course of my employment, unless the Company grants me authorization to do so. I agree that upon separation from employment
with the Company or on demand by the Company during my employment, I will immediately deliver to the Company (and will not keep in my
possession, recreate or deliver to anyone else) any and all Company and MDxHealth group property, including, but not limited to, Company
Confidential Information, Associated Third Party Confidential Information, as well as all devices and equipment belonging to the Company
and MDxHealth group (including computers, handheld electronic devices, telephone equipment, and other electronic devices), Company credit
cards, records, data, notes, notebooks, reports, files, proposals, lists, correspondence, specifications, drawings, blueprints, sketches,
materials, photographs, charts, all other documents and property, and reproductions of any of the aforementioned items that were developed
by me pursuant to my employment with the Company, obtained by me in connection with my employment with the Company, or otherwise belonging
to the Company or its Affiliates, including, without limitation, those records maintained pursuant to Section 2(e). I also consent to
an exit interview to confirm my compliance with this Section 6.


 


		7.	NO
                                            EMPLOYMENT AGREEMENT



 


Nothing in this Agreement changes my status as
an express at-will employee. I agree that unless specifically provided in another writing signed by me and the Board of Directors of
MDxHealth SA, my employment by the Company is not for a definite period of time. Rather, my employment relationship with the Company
is one of employment at will and may be terminated by either myself or the Company at any time, with or without cause.


 






    17


     


    

 


		8.	GENERAL
                                            PROVISIONS



 


(a) 
Governing Law and Jurisdiction. This Agreement will be governed by the laws of the State of California without giving effect to
any choice of law rules or principles that may result in the application of the laws of any jurisdiction other than California. I expressly
agree that the federal courts and/or state courts of the State of California, Orange County, shall have exclusive jurisdiction to adjudicate
any dispute arising out of this Agreement, including any lawsuit filed against me by the Company.


 


(b) 
Entire Agreement. This Agreement, together with the Exhibits herein, sets forth the entire agreement and understanding between
the Company and me relating to the subject matter herein and supersedes all prior discussions, representations and agreements, written
or oral, between us. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective
unless in writing signed by the Board of Directors of MDxHealth SA and me. Any subsequent change or changes in my duties, salary or compensation
will not affect the validity or scope of this Agreement.


 


(c) 
Severability. If one or more of the provisions in this Agreement are deemed void by law, then the remaining provisions will continue
in full force and effect.


 


(d) 
Successors And Assigns. This Agreement and my obligations hereunder will be binding upon my heirs, executors, administrators and
other legal representatives and will be for the benefit of the Company, its successors, and its assigns.


 


(e) 
Remedies. By virtue of the duties and responsibilities attendant with my engagement by the Company, I understand that great loss
and irreparable damage would be suffered by the Company if I should breach any of the terms of this Agreement. I acknowledge that each
such term is reasonably necessary to protect and preserve the interests of the Company. Therefore, in addition to all other remedies
available to the Company at law or in equity, the Company shall be entitled to, without posting a bond, specific performance, a temporary
restraining order and a permanent injunction to prevent a breach or the continuation of a breach of any of the terms of this Agreement.


 


(f) 
Waiver. Waiver by the Company of a breach of any provision of this Agreement will not operate as a waiver of any other or subsequent
breach.


 


(g) 
Survivorship. My obligations under this Agreement, and the rights of the Company hereunder, will survive termination of my employment
with the Company.


 


(h) 
Agreement Read, Understood and Fair. I have carefully read and considered the provisions of this Agreement and agree that all
of the restrictions set forth are fair and reasonable and are reasonably required for the protection of the interests of the Company.
The Company acknowledges that the goodwill and value of the Company is enhanced by these provisions and that said enhancement is desired
by me.


 


(i) 
Effective Date. The Agreement shall be deemed retroactive to the first day of my employment by the Company.


 


[The remainder of this page intentionally left
blank]


 









    18


     


    

 


(j) 
Signatures. This Agreement may be signed in two counterparts, each of which shall be deemed an original, with the same force and
effectiveness as though executed in a single document.


 


	Michael McGarrity	 	 
	 	 	 
	/s/ Michael McGarrity	 	 
	(Signature)	 	 
	 	 	 
	Date:	February 18, 2019	 	 
	 	 	 
	ACCEPTED AND AGREED TO:	 	 
	 	 	 
	MDxHealth, Inc.	 	 
	 	 	 
	By:	/s/ Koen Hoffman	 	/s/ Walter Narajowski
	Name: 	Koen Hoffman	 	Walter Narajowski
	Title:	Chair man	 	REMCO Chair
	Date:	February 18, 2019	 	February 18, 2019
	 	 	 
	 	 	/s/ Joseph Sollee
	 	 	Joseph Sollee
	 	 	EVP Corp Dev & General Counsel
	 	 	February 18, 2019



 






    19


     


    

 





EXHIBIT A


 


LIST OF EXCLUDED INVENTIONS AND ORIGINAL WORKS OF AUTHORSHIP


 


	TITLE	DATE	IDENTIFYING NUMBER OR BRIEF DESCRIPTION



 


 


 


 


 


 


N/A


 


 


 


 


 


 


____ No inventions or improvements


 


____ Additional sheets attached


 


	Signature of Employee:	/s/ Michael McGarrity	 
	Print Name of Employee:	Michael McGarrity	 
	Date:	2/18/19	 



 









    20


     


    

 


EXHIBIT B


CALIFORNIA LABOR CODE SECTION 2870


EMPLOYMENT AGREEMENTS, ASSIGNMENT OF RIGHTS


 


California Labor Code § 2870. Invention on Own Time - Exemption
from Agreement.


 


		(a)	Any provision in an employment agreement which provides that an employee
                                            shall assign, or offer to assign, any of his or her rights in an invention to his or her
                                            employer shall not apply to an invention that the employee developed entirely on his or her
                                            own time without using the employer’s equipment, supplies, facilities, or trade secret
                                            information except for those inventions that either:



 


		(1)	Relate at the time of conception or reduction to practice of the invention
                                            to the employer’s business, or actual or demonstrably anticipated research or development
                                            of the employer.



 


		(2)	Result from any work performed by the employee for the employer.



 


		(b)	To the extent a provision in an employment agreement purports to require
                                            an employee to assign an invention otherwise excluded from being required to be assigned
                                            under subdivision (a), the provision is against the public policy of this state and is unenforceable.



 






    21


     


    

 


At-Will Executive Employee Agreement
with Severance


 





EXHIBIT C


 


MDxHealth, Inc.


 


TERMINATION CERTIFICATION


 


This is to certify that I do not have in my possession, nor have I
failed to return, any devices, records, software, data, notes, reports, proposals, lists, and sources of customers, lists of employees,
proposals to customers, drafts of proposals, business plans and projections, reports, job notes, correspondence, specifications, drawings,
blueprints, sketches, materials, equipment, other documents or property, or reproductions of any aforementioned items belonging to MDxHealth,
Inc. (“Company”), its parent, subsidiaries, affiliates, successors or assigns (together “Affiliated Entities”).


 


I further certify that I have complied with all terms of the Company’s
Proprietary Information and Inventions Agreement signed by me, including the reporting of any inventions and original works of authorship
(as defined therein) conceived or made by me (solely or jointly with others) covered by that Agreement.


 


I further agree that, in compliance with the Proprietary Information
and Inventions Agreement, I will preserve as confidential all trade secrets, confidential knowledge, data or other proprietary information
relating to products, processes, know-how, designs, formulas, developmental or experimental work, computer programs, data bases, other
original works of authorship, customer lists, business plans, financial information or other subject matter pertaining to any business
of the Company and Affiliated Entities, and their customers, consultants or licensees.


 


	Date: 	 	 	 
	 	 	 	Michael McGarrity
	 	 	 	 
	 	 	 	 
	 	 	 	Signature



 


 


22